Latest Strong buzz on streets –
Dilip Sanghvi of Sun Pharma has acquired additional 2% stake in the company in the past 15 days thereby totaling close to 5%.
Sun Pharma and Ranbaxy are going to announce strategic tie up soon .
Ranbaxy will use the FDA approved manufacturing facilities of Sun Pharma to supply drugs to US. In turn Ranbaxy will delist the shares at Rs. 750 per share within a month.
Sources at daichi say that after the recent meeting of commerce ministry, the US FDA officials have assured that the Tonsa plant of Ranbaxy will get approval soon.